{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:20:45Z","timestamp":1790115645346,"version":"4.0.1"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2314-B-039-002-"],"award-info":[{"award-number":["108-2314-B-039-002-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX108-10731NI"],"award-info":[{"award-number":["NHRI-EX108-10731NI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital, Taiwan","doi-asserted-by":"publisher","award":["DMR-108-BC-2"],"award-info":[{"award-number":["DMR-108-BC-2"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence","doi-asserted-by":"publisher","award":["MOHW107-TDU-B-212-123004"],"award-info":[{"award-number":["MOHW107-TDU-B-212-123004"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,4,24]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Clozapine has been regarded as the last-line antipsychotic agent for patients with refractory\nschizophrenia. However, many patients remain unresponsive to clozapine, referred to as \u201cclozapineresistant\u201d,\n\u201cultra-treatment-resistant\u201d, or remain in incurable state. There has been no convincing evidence\nfor augmentation on clozapine so far. Novel treatments including numerous N-methyl-Daspartate\n(NMDA) receptor (NMDAR) enhancers, such as glycine, D-serine, D-cycloserine, and Nmethylglycine\n(sarcosine) failed in clinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Earlier, the inhibition of D-amino acid oxidase (DAAO) that may metabolize D-amino acids and activate\nNMDAR has been reported to be beneficial for patients with schizophrenia receiving antipsychotics\nexcept for clozapine. A recent randomized, double-blind, placebo-controlled clinical trial found\nthat add-on sodium benzoate, a DAAO inhibitor, improved the clinical symptoms in patients with clozapine-\nresistant schizophrenia, possibly through DAAO inhibition (and thereby NMDAR activation)\nand antioxidation as well; additionally, sodium benzoate showed no obvious side effects, indicating\nthat the treatment is safe at doses up to 2 g per day for 6 weeks. More studies are warranted to elucidate\nthe mechanisms of sodium benzoate for the treatment of schizophrenia and the etiology of this\nsevere brain disease. If the finding can be reconfirmed, this approach may bring new hope for the\ntreatment of the most refractory schizophrenia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>This review summarizes the current status of clinical trials and related mechanisms for treatmentresistant,\nespecially, clozapine-resistant schizophrenia. The importance of understanding the molecular circuit\nswitches is also highlighted which can restore brain function in patients with schizophrenia. Future\ndirections in developing better treatments for the most difficult to cure schizophrenia are also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450120666191011163539","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T12:46:01Z","timestamp":1572353161000},"page":"610-615","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant"],"prefix":"10.2174","volume":"21","author":[{"given":"Chieh-Hsin","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yuan","family":"Lane","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","author":"Remington G.","unstructured":"Remington G.; Addington D.; Honer W.; Ismail Z.; Raedler T.; Teehan M.;  in: canadian journal of psychiatry. SAGE Publications Inc. 2017;\n\t62: pp. 604-16.","DOI":"10.1177\/0706743717720448"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpsychires.2018.11.005","volume":"108","author":"Bartoli F.","year":"2019","unstructured":"Bartoli F.; Crocamo C.; Di Brita C.; Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. J Psychiatr Res 2019,108,24-33","journal-title":"J Psychiatr Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12888-019-2204-6","volume":"19","author":"Lin A.S.","year":"2019","unstructured":"Lin A.S.; Chan H.Y.; Peng Y.C.; Chen W.J.; Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study. BMC Psychiatry 2019,19(1),220","journal-title":"BMC Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","author":"Siskind D.J.","unstructured":"Siskind D.J.; Lee M.; Ravindran A.; Zhang Q.; Ma E.; Motamarri B.;   In: Australian and New\n\tZealand Journal of Psychiatry. SAGE Publications Inc. 2018; 52:\n\tpp. 751-67.","DOI":"10.1177\/0004867418772351"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0269881118822171","volume":"33","author":"Wagner E.","year":"2019","unstructured":"Wagner E.; L\u00f6hrs L.; Siskind D.; Honer W.G.; Falkai P.; Hasan A.; Clozapine augmentation strategies \u2013 a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology SAGE Publications Ltd 2019,33,423-435","journal-title":"Journal of Psychopharmacology SAGE Publications Ltd"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.biopsych.2018.06.001","volume":"84","author":"Harrison P.J.","year":"2018","unstructured":"Harrison P.J.; D-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? Biol Psychiatry [Internet2018,84(6),396-398","journal-title":"Biol Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopsych.2009.01.002","volume":"65","author":"Hashimoto K.","year":"2009","unstructured":"Hashimoto K.; Fujita Y.; Horio M.; Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009,65(12),1103-1106","journal-title":"Biol Psychiatry"},{"key":"ref=8","author":"Lane H-Y.","unstructured":"Lane H-Y.; Lin C-H.; Green M.F.; Hellemann G.; Huang C-C.; Chen P-W.;  \n\t et al. Add-on treatment of benzoate for schizophrenia: a randomized,\n\tdouble-blind, placebo-controlled trial of D-amino acid\n\toxidase inhibitor. JAMA psychiatry [Internet] 2013 [cited 2019\n\tSep 19];70(12): 1267-75. Available from:\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24089054\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24089054"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","volume":"18","author":"Lin C.Y.","year":"2017","unstructured":"Lin C.Y.; Liang S.Y.; Chang Y.C.; Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 2017,18(5),357-368","journal-title":"World J Biol Psychiatry"},{"key":"ref=10","author":"Miyamoto S","unstructured":"Miyamoto S; Jarskog LF; Fleischhacker WW;   Schizophrenia:\n\tWhen clozapine fails. Current Opinion in Psychiatry. Lippincott\n\tWilliams and Wilkins 2015; 28: pp. 243-8."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.biopsych.2017.12.006","volume":"84","author":"Lin C.H.","year":"2018","unstructured":"Lin C.H.; Lin C.H.; Chang Y.C.; Sodium benzoate, a d-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2018,84(6),422-432","journal-title":"Biol Psychiatry"},{"key":"ref=12","author":"Krystal JH","year":"2018","unstructured":"Krystal JH;  Food preservative enhances schizophrenia treatment 2018","journal-title":"Food preservative enhances schizophrenia treatment"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.biopsych.2017.11.032","volume":"83","author":"Frankle W.G.","year":"2018","unstructured":"Frankle W.G.; Paris J.; Himes M.; Mason N.S.; Mathis C.A.; Narendran R.; Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia. Biol Psychiatry 2018,83(8),707-714","journal-title":"Biol Psychiatry"},{"key":"ref=14","volume":"Vol. 10","author":"Amato D.","year":"2019","unstructured":"Amato D.; Kruyer A.; Samaha A.N.; Heinz A.;  Hypofunctional dopamine uptake and antipsychotic treatment-resistant schizophrenia 2019,Vol. 10","journal-title":"Hypofunctional dopamine uptake and antipsychotic treatment-resistant schizophrenia"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.009","author":"Sonnenschein SF","unstructured":"Sonnenschein SF; Grace AA;  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia Neuropharmacology\n\t2019S0028-3908(19)30159-5","journal-title":"Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia Neuropharmacology\n\t2019S0028-3908(19)30159-5"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","volume":"85","author":"Jauhar S.","year":"2019","unstructured":"Jauhar S.; Veronese M.; Nour M.M.; The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry 2019,85(1),79-87","journal-title":"Biol Psychiatry"},{"key":"ref=17","author":"Kaar S.J.","unstructured":"Kaar S.J.; Natesan S.; McCutcheon R.; Howes O.D.;  Antipsychotics:\n\tMechanisms underlying clinical response and side-effects and novel\n\ttreatment approaches based on pathophysiology. Neuropharmacology\n\t[Internet] 2019 [cited 2019 Sep 19];107704 Available from:\n                     https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081930262X"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1192\/bjp.181.3.184","volume":"181","author":"Williams L.","year":"2002","unstructured":"Williams L.; Newton G.; Roberts K.; Finlayson S.; Brabbins C.; Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002,181,184-187","journal-title":"Br J Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.1.81-a","author":"Lu M.L.","unstructured":"Lu M.L.; Lane H.Y.;  Adjunctive fluvoxamine with clozapine  Br J\n  Psychiatry [Internet] 2003 [cited 2019 Sep 19];182-81. Available from\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12509328\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12509328","journal-title":"Adjunctive fluvoxamine with clozapine"},{"key":"ref=20","volume":"Vol. 18","author":"Jeon S.W.","year":"2017","unstructured":"Jeon S.W.; Kim Y.K.;  Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome 2017,Vol. 18","journal-title":"Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome"},{"key":"ref=21","author":"Jankowska A.","unstructured":"Jankowska A.; Sata\u0142a G.; Partyka A.; Weso\u0142owska A.; Bojarski A.J.; Paw\u0142owski M.;  Discovery and development of non-dopaminergic agents for the treatment of schizophrenia: overview of the preclinical and early clinical studies Curr Med Chem [Internet]\n\t2019 [cited 2019 Sep 19];26 Available from:","journal-title":"Discovery and development of non-dopaminergic agents for the treatment of schizophrenia: overview of the preclinical and early clinical studies Curr Med Chem [Internet]\n\t2019 [cited 2019 Sep 19];26 Available from:"},{"key":"ref=22","author":"Chuhma N.","unstructured":"Chuhma N.; Mingote S.; Kalmbach A.; Yetnikoff L.; Rayport S.;  Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia  Biol Psychiatry [Internet]\n\t2017 [cited 2019 Sep 20];81(1): 43-51 Available from:","journal-title":"Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia  Biol Psychiatry [Internet]\n\t2017 [cited 2019 Sep 20];81(1): 43-51 Available from:"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biopsycho.2015.10.013","volume":"116","author":"Catts V.S.","year":"2016","unstructured":"Catts V.S.; Lai Y.L.; Weickert C.S.; Weickert T.W.; Catts S.V.; A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits? Biol Psychol 2016,116,57-67","journal-title":"Biol Psychol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.biopsych.2017.01.004","volume":"81","author":"Krystal J.H.","year":"2017","unstructured":"Krystal J.H.; Anticevic A.; Yang G.J.; Dragoi G.; Driesen N.R.; Wang X.J.; Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective. Elsevier, USA. Biol Psychiatry 2017,81,874-885","journal-title":"Biol Psychiatry"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.biopsych.2018.01.006","volume":"Vol 83","author":"Javitt D.C.","year":"2018","unstructured":"Javitt D.C.; Excitatory amino acids in schizophrenia: both what you have, and what you do with them. Elsevier, USA. Biol Psychiatry 2018,Vol 83,470-472","journal-title":"Biol Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.biopsych.2018.09.009","volume":"85","author":"Iwata Y.","year":"2019","unstructured":"Iwata Y.; Nakajima S.; Plitman E.; Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3t proton magnetic resonance spectroscopy study. Biol Psychiatry 2019,85(7),596-605","journal-title":"Biol Psychiatry"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biopsych.2008.06.011","volume":"Vol 64","author":"Krystal J.H.","year":"2008","unstructured":"Krystal J.H.; Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia. elsevier, USA. Biol Psychiatry 2008,Vol 64,358-360","journal-title":"Biol Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.2174\/1566524015666150330143008","author":"Ohgi Y.","unstructured":"Ohgi Y.; Futamura T.; Hashimoto K.;  Glutamate signaling in synaptogenesis and nmda receptors as potential therapeutic targets for psychiatric disorders  Curr Mol Med [Internet] 2015 [cited 2019 Sep 19];\n\t15(3): 206-1 Available from:","journal-title":"Glutamate signaling in synaptogenesis and nmda receptors as potential therapeutic targets for psychiatric disorders  Curr Mol Med [Internet] 2015 [cited 2019 Sep 19];\n\t15(3): 206-1 Available from:"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.biopsych.2017.12.019","volume":"84","author":"D\u2019Souza D.C.","year":"2018","unstructured":"D\u2019Souza D.C.; Carson R.E.; Driesen N.; Johannesen J.; Ranganathan M.; Krystal J.H.; Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor pf-03463275 in healthy and schizophrenia subjects. Biol Psychiatry 2018,84(6),413-421","journal-title":"Biol Psychiatry"},{"key":"ref=30","author":"Nucifora F.C.","year":"2018","unstructured":"Nucifora F.C.; Woznica E.; Lee B.J.; Cascella N.; Sawa A.; Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis 2018","journal-title":"Neurobiol Dis"},{"key":"ref=31","author":"Chang H-J.","unstructured":"Chang H-J.; Lane H-Y.; Tsai G.E.;  NMDA pathology and treatment of schizophrenia Curr Pharm Des [Internet] 2014 [cited 2019 Sep\n\t19];20(32): 5118-26 Available from:","journal-title":"NMDA pathology and treatment of schizophrenia Curr Pharm Des [Internet] 2014 [cited 2019 Sep\n\t19];20(32): 5118-26 Available from:"},{"key":"ref=32","author":"Kantrowitz J.T.","unstructured":"Kantrowitz J.T.; Epstein M.L.; Beggel O.; Rohrig S.; Lehrfeld J.M.; Revheim N.;  Neurophysiological mechanisms of cortical plasticity\nimpairments in schizophrenia and modulation by the NMDA\nreceptor agonist D-serine. Brain [Internet] 2016 [cited 2019 Sep\n\t19];139(Pt 12): 3281-95. Available from\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27913408\">http:\/\/www.ncbi.nlm. nih.gov\/pubmed\/27913408"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","volume":"60","author":"Lane H.Y.","year":"2006","unstructured":"Lane H.Y.; Huang C.L.; Wu P.L.; Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006,60(6),645-649","journal-title":"Biol Psychiatry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.eurpsy.2004.12.007","volume":"20","author":"Kontaxakis V.P.","year":"2005","unstructured":"Kontaxakis V.P.; Ferentinos P.P.; Havaki-Kontaxaki B.J.; Roukas D.K.; Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005,20(5-6),409-415","journal-title":"Eur Psychiatry"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1017\/S109285291900124X","author":"Krogmann A.","unstructured":"Krogmann A.; Peters L.; von Hardenberg L.; B\u00f6deker K.; N\u00f6hles V.B.; Correll C.U.;  Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities CNS Spectr [Internet] 2019 [cited 2019 Sep 19];24(S1): 38-69.\n\tAvailable from:\n                     https:\/\/www.cambridge.org\/core\/product\/identifier\/S109285291900124X\/type\/journal_article","journal-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.aca.2011.02.039","volume":"691","author":"Zhang H.","year":"2011","unstructured":"Zhang H.; Qi L.; Qiao J.; Mao L.; Determination of sodium benzoate by chiral ligand exchange CE based on its inhibitory activity in D-amino acid oxidase mediated oxidation of D-serine. Anal Chim Acta 2011,691(1-2),103-109","journal-title":"Anal Chim Acta"},{"key":"ref=37","author":"Johnson W","unstructured":"Johnson W; Bergfeld WF; Belsito D V; Hill RA; Klaassen CD; Liebler DC;  Safety assessment of benzyl alcohol, benzoic acid and its salts, and benzyl benzoate  Int J Toxicol 2017;\n\t36(3_suppl): 5S-30S.","journal-title":"Safety assessment of benzyl alcohol, benzoic acid and its salts, and benzyl benzoate"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2174\/1381612811319140002","volume":"19","author":"Sacchi S.","year":"2013","unstructured":"Sacchi S.; Rosini E.; Pollegioni L.; Molla G.; D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des 2013,19(14),2499-2511","journal-title":"Curr Pharm Des"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.4049\/jimmunol.0803336","volume":"183","author":"Brahmachari S.","year":"2009","unstructured":"Brahmachari S.; Jana A.; Pahan K.; Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 2009,183(9),5917-5927","journal-title":"J Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrn.2015.19","volume":"17","author":"Hardingham G.E.","year":"2016","unstructured":"Hardingham G.E.; Do K.Q.; Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci 2016,17(2),125-134","journal-title":"Nat Rev Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1017\/neu.2019.14","volume":"31","author":"Solberg D.K.","year":"2019","unstructured":"Solberg D.K.; Refsum H.; Andreassen O.A.; Bentsen H.; A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta Neuropsychiatr 2019,31(4),202-212","journal-title":"Acta Neuropsychiatr"},{"key":"ref=42","author":"Tsugawa S.","year":"2019","unstructured":"Tsugawa S.; Noda Y.; Tarumi R.; Mimura Y.; Yoshida K.; Iwata Y.;  Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis Journal of Psychopharmacology 2019","journal-title":"Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis Journal of Psychopharmacology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgme.2014.11.010","volume":"114","author":"Lennerz B.S.","year":"2015","unstructured":"Lennerz B.S.; Vafai S.B.; Delaney N.F.; Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans. Mol Genet Metab 2015,114(1),73-79","journal-title":"Mol Genet Metab"},{"key":"ref=44","author":"Oxenkrug G.","unstructured":"Oxenkrug G.; van der Hart M.; Roeser J.; Summergrad P.;  Anthranilic\n\tAcid: A potential biomarker and treatment target for schizophrenia.\n\tann psychiatry Ment Heal [Internet] [cited 2019 Sep 19];4(2)\n\tAvailable from:\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27042691\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27042691"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/neu.2015.1","volume":"27","author":"Matsuura A.","year":"2015","unstructured":"Matsuura A.; Fujita Y.; Iyo M.; Hashimoto K.; Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatr 2015,27(3),159-167","journal-title":"Acta Neuropsychiatr"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11064-016-1838-8","volume":"41","author":"Sershen H.","year":"2016","unstructured":"Sershen H.; Hashim A.; Dunlop D.S.; Suckow R.F.; Cooper T.B.; Javitt D.C.; Modulating NMDA receptor function with d-amino acid oxidase inhibitors: Understanding functional activity in PCP-treated mouse model. Neurochem Res 2016,41(1-2),398-408","journal-title":"Neurochem Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.biopsych.2013.08.010","volume":"75","author":"Lin C.H.","year":"2014","unstructured":"Lin C.H.; Chen P.K.; Chang Y.C.; Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2014,75(9),678-685","journal-title":"Biol Psychiatry"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/0269881119849815","volume":"33","author":"Lin C.H.","year":"2019","unstructured":"Lin C.H.; Chen P.K.; Wang S.H.; Lane H.Y.; Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol (Oxford) 2019,33(8),1030-1033","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fpsyt.2018.00713","volume":"9","author":"Madeira C.","year":"2018","unstructured":"Madeira C.; Alheira F.V.; Calcia M.A.; Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia. Front Psychiatry 2018,9,713","journal-title":"Front Psychiatry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1073\/pnas.1817885116","volume":"116","author":"Sedlak T.W.","year":"2019","unstructured":"Sedlak T.W.; Paul B.D.; Parker G.M.; The glutathione cycle shapes synaptic glutamate activity. Proc Natl Acad Sci USA 2019,116(7),2701-2706","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"10163","DOI":"10.1038\/s41598-018-28332-x","volume":"8","author":"Keller S.","year":"2018","unstructured":"Keller S.; Punzo D.; Cuomo M.; DNA methylation landscape of the genes regulating D-serine and D-aspartate metabolism in post-mortem brain from controls and subjects with schizophrenia. Sci Rep 2018,8(1),10163","journal-title":"Sci Rep"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.biopsych.2018.01.007","volume":"Vol 83","author":"Srivastava R.","year":"2018","unstructured":"Srivastava R.; Faust T.; Ramos A.; Ishizuka K.; Sawa A.; Dynamic changes of the mitochondria in psychiatric illnesses: new mechanistic insights from human neuronal models. Elsevier, USA. Biol Psychiatry 2018,Vol 83,751-760","journal-title":"Biol Psychiatry"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0393-5","author":"Dwir D.","year":"2019","unstructured":"Dwir D.; Giangreco B.; Xin L.; MMP9\/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory\/excitatory imbalance: a reverse translation study in schizophrenia patients. Mol Psychiatry 2019","journal-title":"Mol Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jpsychires.2015.10.007","volume":"72","author":"Lin C.H.","year":"2016","unstructured":"Lin C.H.; Lin P.P.; Lin C.Y.; Decreased mRNA expression for the two subunits of system xc(-), SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. J Psychiatr Res 2016,72,58-63","journal-title":"J Psychiatr Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/mp.2008.47","volume":"13","author":"Burnet P.W.J.","year":"2008","unstructured":"Burnet P.W.J.; Eastwood S.L.; Bristow G.C.; D-amino acid oxidase activity and expression are increased in schizophrenia. Mol Psychiatry 2008,13(7),658-660","journal-title":"Mol Psychiatry"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"14849","DOI":"10.1038\/s41598-017-13951-7","volume":"7","author":"Lin C.H.","year":"2017","unstructured":"Lin C.H.; Yang H.T.; Chiu C.C.; Lane H.Y.; Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Sci Rep 2017,7(1),14849","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.80]","author":"Lin C-H.","unstructured":"Lin C-H.; Chang H-T.; Chen Y-J.; Lin C-H.; Huang C-H.; Tun R.;  Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals Mol Psychiatry [Internet]2014 [cited 2019 Jul 14];19(6): 636-7. Available from:\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.nature.com\/articles\/mp201380\">http:\/\/www.nature.com\/articles\/mp201380","journal-title":"Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13063-019-3232-8","volume":"20","author":"Lim C.","year":"2019","unstructured":"Lim C.; Baker A.; Saha S.; Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis. Trials 2019,20(1),203","journal-title":"Trials"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T17:21:41Z","timestamp":1590686501000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175607\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666191011163539","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}